Stock Taper
OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS
PBLS
PARABILIS MEDICINES, INC.
NASDAQ
$41.73
▲ UP 2.08% (0.85)

KEY STATISTICS

Market Cap$4.86 B
52w High$42.49
52w Low$24.51
Dividend Yield—
Frequency—
P/E-47.42
Volume9.09M
Shares Out.116.56M

COMPANY

LEADERSHIP

Mathai Mammen
CHIEF EXECUTIVE
Mathai Mammen

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 10, 2026
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
145

PRICE TARGET

Target High$40.00
Target Low$40.00
Target Median$40.00
Target Consensus$40.00

PRICE

$41.73 ▲ UP 2.08% (+$0.85)
$39.75$40.50$41.25$42.009:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM41.73

About Parabilis Medicines, Inc.

http://www.parabilismed.com ↗

Fog Pharmaceuticals, Inc., founded in 2015 in Cambridge, MA, is a clinical-stage biotech developing cell-penetrating miniproteins to target and neutralize cancer-causing proteins inside cancer cells.

INDUSTRY

Biotechnology

A PRODUCT PARABILIS MEDICINES, INC. IS KNOWN FOR

Zolucatetide
Zolucatetide

Zolucatetide, a first-in-class clinical-stage cancer drug from Parabilis Medicines' Helicon™ platform, targets the β-catenin/TCF interaction, with Phase 3 trials planned for desmoid tumors and potential applications in other cancers.

COMPETITORS

COMPETITOR
IMNM COMPARE
JAZZ COMPARE
MRK COMPARE
RXRX COMPARE
TPST COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
19
LISTED HERE
4
RANKED BY POSITION SIZE
VTS.AX
0.00% · 1.1M
FBCG
0.03% · 60.9K
HLTH
2.64% · 5.9K
RFLR
0.12% · 2.8K

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book4
Overall Score2

INSIDER TRADES

★
DIRECTOR
Tendler Craig
Purchase · 20.3K shares
2026-08-22
★
DIRECTOR
Tendler Craig
— · 16.2K shares
2026-08-22
★
DIRECTOR, 10 PERCENT OWNER:
RA CAPITAL MANAGEMENT, L.P.
Purchase · 33.0K shares
2026-07-20
★
DIRECTOR, 10 PERCENT OWNER:
RA CAPITAL MANAGEMENT, L.P.
Purchase · 21.7K shares
2026-07-21